ReviewExpert opinion on drug safety2016
Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Review in Expert opinion on drug safety, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced Streptococcus and increased Erysipelotrichaceae in rectal microbiota.Scientific reports · 2018Trial
- Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.Journal of acquired immune deficiency syndromes (1999) · 2017Trial
- Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine.Antimicrobial agents and chemotherapy · 2016Trial
- Knowledge, attitudes, and behavioural intention towards HIV pre-exposure prophylaxis among health science students in South Africa: cross-sectional study.Frontiers in public health · 2026Article
- Effect of antiretrovirals on renal function in people taking HIV pre-exposure prophylaxis.Revista latino-americana de enfermagem · 2025Article
- Article
- The impact of HIV antiretroviral therapy on gut microbiota: the need for well-designed longitudinal studies.Journal of infection in developing countries · 2024Review
- Applying a Three-Tier Approach to Address Gaps in Oral Pre-Exposure Prophylaxis Uptake and Continuity in Uganda: A Mixed Methods Approach.Global health, science and practice · 2024Article
- Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01.Nature communications · 2023Article
- A qualitative study on the clinical safety and user experiences of female condoms for anal intercourse among men who have sex with men in Shanghai, China.Frontiers in public health · 2023Article
- Knowledge domain and emerging trends in HIV pre-exposure prophylaxis: A visualization analysisFrontiers in microbiology · 2023Article
- Impact of Tenofovir Disoproxil Fumarate Use During Pregnancy on Maternal Bone Mineral Density.The Pediatric infectious disease journal · 2022Article
- HIV Pre-exposure Prophylaxis and Its Impact on the Gut Microbiome in Men Having Sex With Men.Frontiers in microbiology · 2022Review
- Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients.Scientific reports · 2021Article
- Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming.AIDS and behavior · 2020Article
- Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020.Southern African journal of HIV medicine · 2020Article
- Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?Current HIV/AIDS reports · 2019Review
- Article
- Molecular Docking Studies of HIV-1 Resistance to Reverse Transcriptase Inhibitors: Mini-Review.Molecules (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
introductionTenofovir disoproxil fumarate (TDF)-based pre-exposure prophylaxis is a novel HIV prevention strategy for individuals at increased sexual risk for HIV infection. For any biomedical prevention intervention, the bar for tolerating adverse effects in healthy persons is high compared to therapeutic interventions. AREAS COVERED: We provide a concise summary of the clinical safety of TDF-based pre-exposure prophylaxis with focus on TDF-related effects on tolerability, kidney function, bone density, HIV resistance, sexual and reproductive health. The evidence base for this review is derived from a literature search of both randomized and observational studies evaluating efficacy and safety of TDF-based PrEP, TDF alone or in combination with emtricitabine, identified from PUBMED and EMBASE electronic databases, clinicaltrials.gov and major HIV conferences. EXPERT OPINION: TDF-based pre-exposure prophylaxis is a potent intervention against HIV acquisition when taken which is generally safe and well tolerated. The risk of the small, non-progressive, and reversible decline in glomerular filtration rate and bone mineral density as well as the potential selection for drug resistance associated with PrEP are outweighed, at the population level and broadly for individuals, by PrEP's substantial reduction in the risk of HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.